85 related articles for article (PubMed ID: 20551298)
1. Bile and gallbladder tissue concentrations of moxifloxacin in patients with acute cholecystitis.
Stein GE; Smith CL; Peloquin CA; Mosher B; Dybas L; Kepros JP
Ann Pharmacother; 2010; 44(7-8):1346-7. PubMed ID: 20551298
[No Abstract] [Full Text] [Related]
2. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections.
Ober MC; Hoppe-Tichy T; Köninger J; Schunter O; Sonntag HG; Weigand MA; Encke J; Gutt C; Swoboda S
J Antimicrob Chemother; 2009 Nov; 64(5):1091-5. PubMed ID: 19734170
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based review of moxifloxacin.
O'Brien TP
Int Ophthalmol Clin; 2006; 46(4):61-72. PubMed ID: 17060792
[No Abstract] [Full Text] [Related]
4. Penetration of moxifloxacin into liver tissue.
Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
[TBL] [Abstract][Full Text] [Related]
5. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose.
Wacke R; Förster S; Adam U; Mundkowski RG; Klar E; Hopt UT; Drewelow B
J Antimicrob Chemother; 2006 Nov; 58(5):994-9. PubMed ID: 16956903
[TBL] [Abstract][Full Text] [Related]
6. Penetration and accumulation of moxifloxacin in uterine tissue.
Stass H; Kubitza D; Aydeniz B; Wallwiener D; Halabi A; Gleiter C
Int J Gynaecol Obstet; 2008 Aug; 102(2):132-6. PubMed ID: 18501909
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacodynamic profile and clinical efficacy of moxifloxacin ophthalmic solution (Vegamox 0.5% ophthalmic solution].
Watanabe M; Ishizuka K; Ikemoto T
Nihon Yakurigaku Zasshi; 2007 May; 129(5):375-85. PubMed ID: 17507775
[No Abstract] [Full Text] [Related]
8. Concentration of moxifloxacin in serum and human aqueous humor following a single 400 mg oral dose.
Walter S; Kuchenbecker J; Banditt P; Bode-Böger SM; Behrens-Baumann W
J Cataract Refract Surg; 2007 Mar; 33(3):553-5. PubMed ID: 17321414
[No Abstract] [Full Text] [Related]
9. [Chemotherapy for biliary tract infection (XXXIII). Tissue concentration of NY-198 in gallbladder, biliary excretion and clinical effects].
Tanimura H; Aoki Y; Uesaka K; Kasano Y; Nakai T; Kitamura T; Mukaihara S; Tamura K; Yotsumoto F; Terao R
Nihon Geka Hokan; 1988 Sep; 57(5):381-99. PubMed ID: 3251425
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis.
Alffenaar JW; van Altena R; Bökkerink HJ; Luijckx GJ; van Soolingen D; Aarnoutse RE; van der Werf TS
Clin Infect Dis; 2009 Oct; 49(7):1080-2. PubMed ID: 19712035
[TBL] [Abstract][Full Text] [Related]
11. Moxifloxacin in multidrug-resistant tuberculosis: is there any indication for therapeutic drug monitoring?
Manika K; Chatzika K; Zarogoulidis K; Kioumis I
Eur Respir J; 2012 Oct; 40(4):1051-3. PubMed ID: 23024328
[No Abstract] [Full Text] [Related]
12. Serum and prostatic tissue concentrations of moxifloxacin in patients undergoing transurethral resection of the prostate.
Wagenlehner FM; Lunz JC; Kees F; Wieland W; Naber KG
J Chemother; 2006 Oct; 18(5):485-9. PubMed ID: 17127224
[TBL] [Abstract][Full Text] [Related]
13. Vitreal penetration of oral moxifloxacin in humans.
Lott MN; Fuller JJ; Hancock HA; Singh J; Singh H; McGwin G; Marcus DM
Retina; 2008 Mar; 28(3):473-6. PubMed ID: 18327141
[TBL] [Abstract][Full Text] [Related]
14. Penetration of moxifloxacin into rat mandibular bone and soft tissue.
Cachovan G; Nergiz I; Thuss U; Siefert HM; Sobottka I; Oral O; Platzer U; Dogan-Onur O
Acta Odontol Scand; 2009; 67(3):182-6. PubMed ID: 19306136
[TBL] [Abstract][Full Text] [Related]
15. Vitreal penetration of oral and topical moxifloxacin in humans.
Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM
Am J Ophthalmol; 2007 Feb; 143(2):338-40. PubMed ID: 17258525
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin penetration into human gastrointestinal tissues.
Wirtz M; Kleeff J; Swoboda S; Halaceli I; Geiss HK; Hoppe-Tichy T; Büchler MW; Friess H
J Antimicrob Chemother; 2004 May; 53(5):875-7. PubMed ID: 15056642
[TBL] [Abstract][Full Text] [Related]
17. Acute bacterial maxillary sinusitis: time to symptom resolution and return to normal activities with moxifloxacin.
Johnson P; Adelglass J; Rankin B; Sterling R; Keating K; Benson A; Pertel P
Int J Clin Pract; 2008 Sep; 62(9):1366-72. PubMed ID: 18671753
[TBL] [Abstract][Full Text] [Related]
18. Good penetration of moxifloxacin into human abscesses.
Sauermann R; Karch R; Kjellsson MC; Feurstein T; Püspök A; Langenberger H; Böhmdorfer M; Jäger W; Zeitlinger M
Pharmacology; 2012; 90(3-4):146-50. PubMed ID: 22868236
[TBL] [Abstract][Full Text] [Related]
19. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis.
Burkhardt O; Derendorf H; Jäger D; Kumar V; Madabushi R; Röhl K; Barth J
Scand J Infect Dis; 2006; 38(10):904-8. PubMed ID: 17008236
[TBL] [Abstract][Full Text] [Related]
20. Penetration of moxifloxacin into sternal bone of patients undergoing routine cardiopulmonary bypass surgery.
Metallidis S; Charokopos N; Nikolaidis J; Alexiadou E; Lazaraki G; Koumentaki E; Tsona A; Theodoridis G; Nikolaidis P
Int J Antimicrob Agents; 2006 Nov; 28(5):428-32. PubMed ID: 17034992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
